We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
B-cell non-Hodgkin's lymphoma is a type of cancer that originates in the B-cells of the immune system, leading to the growth of tumors in the lymphatic system. It can be aggressive and may require various treatments, especially in cases that are relapsed or refractory.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.